Novo Nordisk A/S
🇩🇰Denmark
- Country
- 🇩🇰Denmark
- Ownership
- Public
- Established
- 1923-01-01
- Employees
- 63.3K
- Market Cap
- $602.2B
- Website
- http://www.novonordisk.com
Comparison of Liraglutide Versus Placebo in Weight Loss Maintenance in Obese Subjects: SCALE - Maintenance
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-10-29
- Last Posted Date
- 2017-11-01
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 422
- Registration Number
- NCT00781937
- Locations
- 🇨🇦
Novo Nordisk Investigational Site, Montreal, Canada
Observational Study Evaluating the Safety of NovoMix® in Type 2 Diabetes Patients Previously Treated With a Human Premix Insulin
- First Posted Date
- 2008-10-20
- Last Posted Date
- 2017-01-11
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 611
- Registration Number
- NCT00775736
- Locations
- 🇱🇺
Novo Nordisk Investigational Site, Luxembourg, Luxembourg
Efficacy, Safety and Preference Study of a Insulin Pen PDS290 vs. a Novo Nordisk Marketed Insulin Pen in Diabetics
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-10-16
- Last Posted Date
- 2017-03-27
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 242
- Registration Number
- NCT00773279
- Locations
- 🇺🇸
Novo Nordisk Investigational Site, Milwaukee, Wisconsin, United States
Observational Study to Evaluate the Effectiveness and Safety of Levemir®, NovoMix® 30 and NovoRapid® in Insulin naïve Subjects With Type 2 Diabetes
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-10-13
- Last Posted Date
- 2016-10-28
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 10408
- Registration Number
- NCT00771680
- Locations
- 🇺🇦
Novo Nordisk Investigational Site, Kiev, Ukraine
To Investigate the Blood Concentration of Liraglutide as Well as the Effects on Glucose and Insulin After 21 Days of Daily Subcutaneous Injections of Liraglutide or Placebo
- First Posted Date
- 2008-09-29
- Last Posted Date
- 2017-01-26
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 37
- Registration Number
- NCT00761540
- Locations
- 🇨🇳
Novo Nordisk Investigational Site, Beijing, Beijing, China
Comparison of Insulin Detemir and NPH With Respect to Lowering the Blood Sugar and Symptoms Experienced by Type 1 Diabetics During Hypoglycaemia
Phase 1
Completed
- Conditions
- First Posted Date
- 2008-09-26
- Last Posted Date
- 2017-01-27
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 25
- Registration Number
- NCT00760448
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Guildford, United Kingdom
Observational Study of NovoMix® 50 for Treatment of Type 2 Diabetics for 12 Months
- First Posted Date
- 2008-09-19
- Last Posted Date
- 2016-10-31
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 270
- Registration Number
- NCT00755833
- Locations
- 🇸🇮
Novo Nordisk Investigational Site, Ljubljana, Slovenia
Switch From Metformin Monotherapy to a Bitherapy With Metformin and Repaglinide
- First Posted Date
- 2008-09-03
- Last Posted Date
- 2023-11-02
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 906
- Registration Number
- NCT00745433
Observational Study on Safety of Self-titration of Once Daily Levemir®
- First Posted Date
- 2008-08-25
- Last Posted Date
- 2017-02-03
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 882
- Registration Number
- NCT00740519
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Crawley, United Kingdom
Observational Study on Efficacy and Safety in Patients Using NovoMix® 30 for the Treatment of Diabetes
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-08-20
- Last Posted Date
- 2016-10-31
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 1068
- Registration Number
- NCT00737776
- Locations
- 🇰🇷
Novo Nordisk Investigational Site, Seoul, Korea, Republic of
© Copyright 2024. All Rights Reserved by MedPath